Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024)
Immunocore Holdings (IMCR) posted Other Accumulated Expenses of $7.5 million for Q1 2024, up 24.49% sequentially from $6.0 million in Q4 2023.
Analysis
Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024) Analysis & Trends
Immunocore Holdings has reported Other Accumulated Expenses for 3 years, with the latest figure at $7.5 million in Q1 2024.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $7.5 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $7.5 million (changed N/A YoY) and the FY2023 annual result came in at $6.0 million, up 62.74% from the prior year.
- Other Accumulated Expenses improved to $7.5 million in Q1 2024 per IMCR's latest filing, from $6.0 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $7.5 million in Q1 2024 and troughed at $3.7 million in Q4 2022.
- A 3-year average of $5.7 million and a median of $6.0 million in 2023 frame the typical range for Other Accumulated Expenses.
- The widest YoY moves for Other Accumulated Expenses: up 62.74% in 2023, down 62.74% in 2023.
- Over 3 years, Other Accumulated Expenses stood at $3.7 million in 2022, then surged by 62.74% to $6.0 million in 2023, then advanced by 24.49% to $7.5 million in 2024.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $7.5 million, $6.0 million, and $3.7 million for Q1 2024, Q4 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 7.46 Mn |
| Dec 31, 2023 | 5.99 Mn |
| Dec 31, 2022 | 3.68 Mn |